Status:
COMPLETED
Sildenafil for Chronic Obstructive Pulmonary Disease
Lead Sponsor:
Kawut, Steven, MD
Collaborating Sponsors:
Pfizer
Conditions:
Pulmonary Disease, Chronic Obstructive
Emphysema
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if sildenafil improves the exercise capacity and lung function of patients with chronic obstructive pulmonary disease.
Detailed Description
Patients with chronic obstructive pulmonary disease (COPD) suffer from impaired exercise capacity and quality-of-life, largely related to shortness of breath. Many of the therapies currently available...
Eligibility Criteria
Inclusion
- Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema
- FEV1/FVC ratio \< 70%
- FEV1 \< 80%
- Stable medication regimen
Exclusion
- COPD exacerbation or hospitalization in the past 3 months
- Heart disease
- Contraindication to sildenafil
- Unrelated lung disease
- Inability to walk or pedal on a stationary bike
- Pregnancy or breast-feeding
- Pulmonary hypertension at rest
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00104637
Start Date
February 1 2005
End Date
November 1 2008
Last Update
May 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia Univeristy, College of Physicians and Surgeons
New York, New York, United States, 10032